Thyroid eye disease (TED) is an autoimmune condition that causes swelling and damage to the tissues around your eyes. There are two phases of TED: an active phase and an inactive phase.

TED is a rare autoimmune disorder in which the muscles and fatty tissues behind the eye become inflamed, causing the eyes to ...

Madam Goh, now 62, had thyroid eye disease (TED), a rare autoimmune disease in which the eye muscles and fatty tissue behind the eyes become inflamed, pushing the eyes forward or causing the eyes and ...

In some cases, you might need surgery to treat any permanent structural changes around the eyes. The disease usually enters an inactive phase after 6 months to 2 years of treatment. Thyroid ...

Topline results have been announced from a Phase 2/3 trial assessing linsitinib for the treatment of active, moderate to ...

Viridian Shares Soar After Latest Trial Success for Thyroid Eye Disease Drug Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

Credit: Getty Images. Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor. Findings showed the proptosis responder rate at week ...

Day two of the J.P Morgan Healthcare Conference rolled on with positive data from Sling Therapeutics Inc. that is leading the company to a phase III study in treating thyroid eye disease. The ...

Unintentional weight loss, shakes and tremors, heart palpitations, and heat intolerance are among some of the telltale signs ...